Antimicrobial resistance (AMR) is a global problem. Unless AMR is addressed, it is estimated that it could cost the global economy over $100 trillion between now and 2050, and by 2050 over 10 million people will die annually from complication of antibiotic-resistant infections. Fedora Pharmaceuticals Inc. is dedicated to the discovery and development of novel antimicrobial agents with activity against multi-drug resistant pathogens. Fedora is privately-held and was founded in 2011 and is headquartered in Edmonton, Alberta, Canada.

 

Fedora has a rich pipeline of antibiotic candidates. Nacubactam is Fedora’s most advanced product and is a beta-lactamase inhibitor. Beta-Lactamases are enzymes that destroy beta-lactam antibiotics, such as penicillins, cephalosporins, and carbapenems (which account for over 60% of all antibiotics prescribed) rendering them ineffective. Nacubactam selectively and effectively inhibits beta-lactamases and hence, return the activity of the antibiotics. Nacubactam has completed several phase 1 clinical trials and is available for licensing as a combination product with meropenem.

​

In addition, Fedora is developing a series of earlier stage antibiotic candidates with the goal of selecting one or more candidates to advance into clinical trials by 2022. 

 

Fedora's management and scientific team of staff and collaborators bring a wealth of knowledge and expertise in drug discovery and development to the challenge of antimicrobial drug development. Together, they have led the discovery and development of an extensive list of anti-infectives, many of which are in clinical use today.